-
1
-
-
41949130070
-
Improved survival in multiple myeloma and the impact of novel therapies
-
Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111 (2008) 2516-2520
-
(2008)
Blood
, vol.111
, pp. 2516-2520
-
-
Kumar, S.K.1
Rajkumar, S.V.2
Dispenzieri, A.3
-
2
-
-
34848833957
-
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
-
Facon T., Mary J.Y., Hulin C., et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370 (2007) 1209-1218
-
(2007)
Lancet
, vol.370
, pp. 1209-1218
-
-
Facon, T.1
Mary, J.Y.2
Hulin, C.3
-
3
-
-
50449086728
-
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
-
San Miguel J.F., Schlag R., Khuageva N.K., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359 (2008) 906-917
-
(2008)
N Engl J Med
, vol.359
, pp. 906-917
-
-
San Miguel, J.F.1
Schlag, R.2
Khuageva, N.K.3
-
4
-
-
0038509089
-
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group
-
International Myeloma Working Group
-
International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.
-
(2003)
Br J Haematol
, vol.121
, pp. 749-757
-
-
-
5
-
-
20644460600
-
International staging system for multiple myeloma
-
Greipp P.R., San Miguel J., Durie B.G.M., et al. International staging system for multiple myeloma. J Clin Oncol 23 (2005) 3412-3420
-
(2005)
J Clin Oncol
, vol.23
, pp. 3412-3420
-
-
Greipp, P.R.1
San Miguel, J.2
Durie, B.G.M.3
-
6
-
-
33847378314
-
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
-
Avet-Loiseau H., Attal M., Moreau P., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 109 (2007) 3489-3495
-
(2007)
Blood
, vol.109
, pp. 3489-3495
-
-
Avet-Loiseau, H.1
Attal, M.2
Moreau, P.3
-
7
-
-
8944220233
-
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francophone du Myélome
-
Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francophone du Myélome. N Engl J Med 335 (1996) 91-97
-
(1996)
N Engl J Med
, vol.335
, pp. 91-97
-
-
Attal, M.1
Harousseau, J.L.2
Stoppa, A.M.3
-
8
-
-
20444433230
-
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
-
Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 (2005) 2487-2498
-
(2005)
N Engl J Med
, vol.352
, pp. 2487-2498
-
-
Richardson, P.G.1
Sonneveld, P.2
Schuster, M.W.3
-
9
-
-
36349010285
-
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
-
Weber D.M., Chen C., Niesvizky R., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357 (2007) 2133-2142
-
(2007)
N Engl J Med
, vol.357
, pp. 2133-2142
-
-
Weber, D.M.1
Chen, C.2
Niesvizky, R.3
-
10
-
-
36349023319
-
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
-
Dimopoulos M., Spencer A., Attal M., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357 (2007) 2123-2132
-
(2007)
N Engl J Med
, vol.357
, pp. 2123-2132
-
-
Dimopoulos, M.1
Spencer, A.2
Attal, M.3
-
11
-
-
84988241358
-
International uniform response criteria for multiple myeloma
-
Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 20 (2006) 1467-1473
-
(2006)
Leukemia
, vol.20
, pp. 1467-1473
-
-
Durie, B.G.1
Harousseau, J.L.2
Miguel, J.S.3
-
12
-
-
0028775544
-
The treatment of multiple myeloma
-
Alexanian R., and Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 330 (1994) 484-489
-
(1994)
N Engl J Med
, vol.330
, pp. 484-489
-
-
Alexanian, R.1
Dimopoulos, M.2
-
13
-
-
0344076348
-
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials
-
Myeloma Trialists' Collaborative Group
-
Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16 (1998) 3832-3842
-
(1998)
J Clin Oncol
, vol.16
, pp. 3832-3842
-
-
-
14
-
-
32644438680
-
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy
-
Facon T., Mary J.Y., Pégourié B., et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 107 (2006) 1292-1298
-
(2006)
Blood
, vol.107
, pp. 1292-1298
-
-
Facon, T.1
Mary, J.Y.2
Pégourié, B.3
-
15
-
-
8644260170
-
Intermediate-dose melphalan improves survival of myeloma patients aged 50-70: results of a randomized controlled trial
-
Palumbo A., Bringhen S., Petrucci M.T., et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50-70: results of a randomized controlled trial. Blood 104 (2004) 3052-3057
-
(2004)
Blood
, vol.104
, pp. 3052-3057
-
-
Palumbo, A.1
Bringhen, S.2
Petrucci, M.T.3
-
16
-
-
41949114641
-
Recent major improvement in long-term survival of younger patients with multiple myeloma
-
Brenner H., Gondos A., and Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111 (2008) 2521-2526
-
(2008)
Blood
, vol.111
, pp. 2521-2526
-
-
Brenner, H.1
Gondos, A.2
Pulte, D.3
-
17
-
-
33644843725
-
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
-
Palumbo A., Bringhen S., Caravita T., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367 (2006) 825-831
-
(2006)
Lancet
, vol.367
, pp. 825-831
-
-
Palumbo, A.1
Bringhen, S.2
Caravita, T.3
-
18
-
-
54049135250
-
Oral melphalan, prednisone and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
-
Palumbo A., Bringhen S., Liberati A.M., et al. Oral melphalan, prednisone and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 112 (2008) 3107-3114
-
(2008)
Blood
, vol.112
, pp. 3107-3114
-
-
Palumbo, A.1
Bringhen, S.2
Liberati, A.M.3
-
19
-
-
68949137225
-
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial
-
Hulin C., Facon T., Rodon P., et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 27 (2009) 3664-3670
-
(2009)
J Clin Oncol
, vol.27
, pp. 3664-3670
-
-
Hulin, C.1
Facon, T.2
Rodon, P.3
-
20
-
-
60849131974
-
Melphalan + prednisone versus melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the Dutch cooperative group HOVON 49 study
-
[abstract]
-
Wijermans P., Schaafsma M., van Norden Y., et al. Melphalan + prednisone versus melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the Dutch cooperative group HOVON 49 study. Blood 112 (2008) 649 [abstract]
-
(2008)
Blood
, vol.112
, pp. 649
-
-
Wijermans, P.1
Schaafsma, M.2
van Norden, Y.3
-
21
-
-
43249097561
-
Thalidomide for treatment of multiple myeloma: ten years later
-
Palumbo A., Facon T., Sonneveld P., et al. Thalidomide for treatment of multiple myeloma: ten years later. Blood 111 (2008) 3968-3977
-
(2008)
Blood
, vol.111
, pp. 3968-3977
-
-
Palumbo, A.1
Facon, T.2
Sonneveld, P.3
-
22
-
-
33748287079
-
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
-
Mateos M.V., Hernandez J.M., Hernandez M.T., et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108 (2006) 2165-2172
-
(2006)
Blood
, vol.108
, pp. 2165-2172
-
-
Mateos, M.V.1
Hernandez, J.M.2
Hernandez, M.T.3
-
23
-
-
42149176608
-
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression
-
Mateos M.V., Hernandez J.M., Hernandez M.T., et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 93 (2008) 560-565
-
(2008)
Haematologica
, vol.93
, pp. 560-565
-
-
Mateos, M.V.1
Hernandez, J.M.2
Hernandez, M.T.3
-
24
-
-
70450275124
-
Updated follow-up and results of subsequent therapy in the phase III VISTA trial: bortezomib plus melphalan-prednisone versus melphalan-prednisone in newly diagnosed multiple myeloma
-
[abstract]
-
San Miguel J.F., Schlag R., Khuageva N.K., et al. Updated follow-up and results of subsequent therapy in the phase III VISTA trial: bortezomib plus melphalan-prednisone versus melphalan-prednisone in newly diagnosed multiple myeloma. Blood 112 (2008) 650 [abstract]
-
(2008)
Blood
, vol.112
, pp. 650
-
-
San Miguel, J.F.1
Schlag, R.2
Khuageva, N.K.3
-
25
-
-
35348923502
-
Melphalan, prednisone and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMENA - Italian Multiple Myeloma Network
-
Palumbo A., Falco P., Corradini P., et al. Melphalan, prednisone and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMENA - Italian Multiple Myeloma Network. J Clin Oncol 25 (2007) 4459-4465
-
(2007)
J Clin Oncol
, vol.25
, pp. 4459-4465
-
-
Palumbo, A.1
Falco, P.2
Corradini, P.3
-
26
-
-
58149376363
-
Thalidomide combinations improve response rates; Results from the MRC IX study
-
[abstract]
-
Morgan G.J., Davies F.E., Owen R.G., et al. Thalidomide combinations improve response rates; Results from the MRC IX study. Blood 110 (2007) 3593 [abstract]
-
(2007)
Blood
, vol.110
, pp. 3593
-
-
Morgan, G.J.1
Davies, F.E.2
Owen, R.G.3
-
27
-
-
33644831033
-
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group
-
Rajkumar S.V., Blood E., Vesole D., et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24 (2006) 431-436
-
(2006)
J Clin Oncol
, vol.24
, pp. 431-436
-
-
Rajkumar, S.V.1
Blood, E.2
Vesole, D.3
-
28
-
-
51049103084
-
Thalidomide-dexamethasone vs. melphalan-prednisone as first line treatment and thalidomide-interferon vs. interferon maintenance therapy in elderly patients with multiple myeloma
-
[abstract]
-
Ludwig H., Tothova E., Hajek R., et al. Thalidomide-dexamethasone vs. melphalan-prednisone as first line treatment and thalidomide-interferon vs. interferon maintenance therapy in elderly patients with multiple myeloma. Blood 110 (2007) 529 [abstract]
-
(2007)
Blood
, vol.110
, pp. 529
-
-
Ludwig, H.1
Tothova, E.2
Hajek, R.3
-
29
-
-
27744492561
-
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
-
Rajkumar S.V., Hayman S.R., Lacy M.Q., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106 (2005) 4050-4053
-
(2005)
Blood
, vol.106
, pp. 4050-4053
-
-
Rajkumar, S.V.1
Hayman, S.R.2
Lacy, M.Q.3
-
30
-
-
34848824393
-
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma
-
Lacy M.Q., Gertz M.A., Dispenzieri A., et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 82 (2007) 1179-1184
-
(2007)
Mayo Clin Proc
, vol.82
, pp. 1179-1184
-
-
Lacy, M.Q.1
Gertz, M.A.2
Dispenzieri, A.3
-
31
-
-
41349095820
-
A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group
-
[abstract]
-
Rajkumar S.V., Jacobus S., Callander N., et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood 110 (2007) 74 [abstract]
-
(2007)
Blood
, vol.110
, pp. 74
-
-
Rajkumar, S.V.1
Jacobus, S.2
Callander, N.3
-
32
-
-
64749086411
-
Bortezomib (Velcade)-melphalan-prednisone (VMP) versus velcade-thalidomide-prednisone (VTP) in elderly untreated multiple myeloma patients: Which is the best partner for Velcade? An alkylating or an immunomodulator agent?
-
[abstract]
-
Mateos M.V., Oriol A., Martinez J., et al. Bortezomib (Velcade)-melphalan-prednisone (VMP) versus velcade-thalidomide-prednisone (VTP) in elderly untreated multiple myeloma patients: Which is the best partner for Velcade? An alkylating or an immunomodulator agent?. Blood 112 (2008) 651 [abstract]
-
(2008)
Blood
, vol.112
, pp. 651
-
-
Mateos, M.V.1
Oriol, A.2
Martinez, J.3
-
33
-
-
70350700998
-
A prospective, randomized, phase III study of bortezomib. Melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed multiple myeloma patients
-
[abstract]
-
Palumbo A., Bringhen S., Rossi D., et al. A prospective, randomized, phase III study of bortezomib. Melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed multiple myeloma patients. Blood 112 (2008) 652 [abstract]
-
(2008)
Blood
, vol.112
, pp. 652
-
-
Palumbo, A.1
Bringhen, S.2
Rossi, D.3
-
34
-
-
33846274225
-
High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
-
Koreth J., Cutler C.S., Djulbegovic B., et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 1 (2007) 183-196
-
(2007)
Biol Blood Marrow Transplant
, vol.1
, pp. 183-196
-
-
Koreth, J.1
Cutler, C.S.2
Djulbegovic, B.3
-
35
-
-
44649149612
-
®-Dexamethasone versus VAD as induction treatment prior to ASCT in newly diagnosed multiple myeloma. Updated results of the IFM2005/01 trial
-
[abstract]
-
®-Dexamethasone versus VAD as induction treatment prior to ASCT in newly diagnosed multiple myeloma. Updated results of the IFM2005/01 trial. Blood 110 (2007) 450 [abstract]
-
(2007)
Blood
, vol.110
, pp. 450
-
-
Harousseau, J.L.1
Mathiot, C.2
Attal, M.3
-
36
-
-
64749108582
-
First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan in patients with newly diagnosed multiple myeloma
-
[abstract]
-
Sonneveld P., van des Holt B., Schmidt-Wolf I.G.H., et al. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan in patients with newly diagnosed multiple myeloma. Blood 112 (2008) 653 [abstract]
-
(2008)
Blood
, vol.112
, pp. 653
-
-
Sonneveld, P.1
van des Holt, B.2
Schmidt-Wolf, I.G.H.3
-
37
-
-
22044452126
-
Superiority of thalidomide and dexamethasone over vincristine-doxorubicine-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma
-
Cavo M., Zamagni E., Tosi P., et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicine-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106 (2005) 35-39
-
(2005)
Blood
, vol.106
, pp. 35-39
-
-
Cavo, M.1
Zamagni, E.2
Tosi, P.3
-
38
-
-
47649091923
-
Lenalidomide, bortezomib, and dexamethasone as front-line therapy for patients with multiple myeloma: preliminary results of a phase 1/2 study
-
[abstract]
-
Richardson P., Jagannath S., Raje N., et al. Lenalidomide, bortezomib, and dexamethasone as front-line therapy for patients with multiple myeloma: preliminary results of a phase 1/2 study. Blood 110 (2007) 187 [abstract]
-
(2007)
Blood
, vol.110
, pp. 187
-
-
Richardson, P.1
Jagannath, S.2
Raje, N.3
-
39
-
-
64749089107
-
Superior complete response rate and progression free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma
-
[abstract]
-
Cavo M., Tacchetti P., Patriarca F., et al. Superior complete response rate and progression free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma. Blood 112 (2008) 158 [abstract]
-
(2008)
Blood
, vol.112
, pp. 158
-
-
Cavo, M.1
Tacchetti, P.2
Patriarca, F.3
-
40
-
-
0036464598
-
2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome randomized trial
-
2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome randomized trial. Blood 99 (2002) 731-735
-
(2002)
Blood
, vol.99
, pp. 731-735
-
-
Moreau, P.1
Facon, T.2
Attal, M.3
-
41
-
-
34347260711
-
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study
-
Cavo M., Tosi P., Zamagni E., et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 25 (2007) 2434-2441
-
(2007)
J Clin Oncol
, vol.25
, pp. 2434-2441
-
-
Cavo, M.1
Tosi, P.2
Zamagni, E.3
-
42
-
-
70450266619
-
Bortezomib and high dose melphalan as conditioning regimen before autologous stem cell transplantation for de novo multiple myeloma: final results of the IFM phase II study VEL/MEL
-
[abstract]
-
Roussel M., Huynh A., Moreau P., et al. Bortezomib and high dose melphalan as conditioning regimen before autologous stem cell transplantation for de novo multiple myeloma: final results of the IFM phase II study VEL/MEL. Blood 112 (2008) 160 [abstract]
-
(2008)
Blood
, vol.112
, pp. 160
-
-
Roussel, M.1
Huynh, A.2
Moreau, P.3
-
43
-
-
33751164196
-
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
-
Attal M., Harousseau J.L., Leyvraz S., et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108 (2006) 3289-3294
-
(2006)
Blood
, vol.108
, pp. 3289-3294
-
-
Attal, M.1
Harousseau, J.L.2
Leyvraz, S.3
-
44
-
-
41349095233
-
Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial
-
Abdelkefi A., Ladeb S., Torjman L., et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 111 (2008) 1805-1810
-
(2008)
Blood
, vol.111
, pp. 1805-1810
-
-
Abdelkefi, A.1
Ladeb, S.2
Torjman, L.3
-
45
-
-
0032748385
-
Antitumor activity of thalidomide in refractory multiple myeloma
-
Singhal S., Mehta J., Desikan R., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341 (1999) 1565-1571
-
(1999)
N Engl J Med
, vol.341
, pp. 1565-1571
-
-
Singhal, S.1
Mehta, J.2
Desikan, R.3
-
46
-
-
0037973279
-
A phase 2 study of bortezomib in relapsed, refractory myeloma
-
Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 (2003) 2609-2617
-
(2003)
N Engl J Med
, vol.348
, pp. 2609-2617
-
-
Richardson, P.G.1
Barlogie, B.2
Berenson, J.3
-
47
-
-
57349171505
-
Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma
-
Moreau P., Coiteux V., Hulin C., et al. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica 93 (2008) 1908-1911
-
(2008)
Haematologica
, vol.93
, pp. 1908-1911
-
-
Moreau, P.1
Coiteux, V.2
Hulin, C.3
-
48
-
-
27644510071
-
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
-
Berenson J.R., Jagannath S., Barlogie B., et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 104 (2005) 2141-2148
-
(2005)
Cancer
, vol.104
, pp. 2141-2148
-
-
Berenson, J.R.1
Jagannath, S.2
Barlogie, B.3
-
49
-
-
20044381304
-
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function
-
Jagannath S., Barlogie B., Berenson J.R., et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 103 (2005) 1195-1200
-
(2005)
Cancer
, vol.103
, pp. 1195-1200
-
-
Jagannath, S.1
Barlogie, B.2
Berenson, J.R.3
-
50
-
-
27644476353
-
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma
-
Richardson P.G., Barlogie B., Berenson J., et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 106 (2005) 2977-2981
-
(2005)
Blood
, vol.106
, pp. 2977-2981
-
-
Richardson, P.G.1
Barlogie, B.2
Berenson, J.3
-
51
-
-
34548539381
-
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression
-
Orlowski R.Z., Nagler A., Sonneveld P., et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25 (2007) 3892-3901
-
(2007)
J Clin Oncol
, vol.25
, pp. 3892-3901
-
-
Orlowski, R.Z.1
Nagler, A.2
Sonneveld, P.3
-
52
-
-
58149384555
-
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
-
Wang M., Dimopoulos M.A., Chen C., et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112 (2008) 4445-4451
-
(2008)
Blood
, vol.112
, pp. 4445-4451
-
-
Wang, M.1
Dimopoulos, M.A.2
Chen, C.3
-
53
-
-
66149109580
-
Lenalidomide (Revlimid (R)), adriamycin and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
-
Knop S., Gerecke C., Liebisch P., et al. Lenalidomide (Revlimid (R)), adriamycin and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 113 (2009) 4137-4143
-
(2009)
Blood
, vol.113
, pp. 4137-4143
-
-
Knop, S.1
Gerecke, C.2
Liebisch, P.3
-
54
-
-
33947575994
-
Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma
-
Palumbo A., Ambrosini M.T., Benevolo G., et al. Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma. Blood 109 (2007) 2767-2772
-
(2007)
Blood
, vol.109
, pp. 2767-2772
-
-
Palumbo, A.1
Ambrosini, M.T.2
Benevolo, G.3
-
56
-
-
44449139385
-
Bisphosphonates et traitements innovants de l'ostéolyse tumorale
-
Debiais F. Bisphosphonates et traitements innovants de l'ostéolyse tumorale. Rev Rhum 75 (2008) 511-522
-
(2008)
Rev Rhum
, vol.75
, pp. 511-522
-
-
Debiais, F.1
-
57
-
-
58949104001
-
Reduction of osteonecrosis of the jaw after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid
-
Dimopoulos M.A., Kastritis E., Bamia C., et al. Reduction of osteonecrosis of the jaw after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20 (2009) 117-120
-
(2009)
Ann Oncol
, vol.20
, pp. 117-120
-
-
Dimopoulos, M.A.1
Kastritis, E.2
Bamia, C.3
-
59
-
-
34548128339
-
The effect of novel antimyeloma agents on bone metabolism of patients with multiple myeloma
-
Terpos E., Dimopoulos M.A., and Sezer O. The effect of novel antimyeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 21 (2007) 1875-1884
-
(2007)
Leukemia
, vol.21
, pp. 1875-1884
-
-
Terpos, E.1
Dimopoulos, M.A.2
Sezer, O.3
-
60
-
-
33644760436
-
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bones metastases from breast cancer
-
Body J.J., Facon T., Coleman R.E., et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bones metastases from breast cancer. Clin Cancer Res 12 (2006) 1221-1228
-
(2006)
Clin Cancer Res
, vol.12
, pp. 1221-1228
-
-
Body, J.J.1
Facon, T.2
Coleman, R.E.3
|